Hunter K, Hlscher C (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
Comprehensive review of currently available glucose-lowering therapies for the treatment of T2DM, focusing on mechanisms of action, pharmacokinetics, pharmacodynamics and safety profiles
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
Safety and Side Effects Common Side Effects While GLP-1 agonists offer significant benefits for managing type 2 diabetes and promoting weight loss, they are not without potential side effects
Missing days during the first month is especially damaging because you never build up to the concentration needed for meaningful appetite suppression and metabolic effects
Mol Cell Neurosci (2016) 70:6875